Sorafenib
Links shared publicly online about this topic
Patients Treated With Sunitinib And Sorafenib Respond To Flu Vaccine
medicalnewstoday.com — “Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical” View full resource at medicalnewstoday.com
Most Recently Shared on June 28, 2011 at 5:06 pm By:
MNT Colds / Flu News Health News
Patients Treated With Sunitinib And Sorafenib Respond To Flu Vaccine http://mnt.to/3XDN #flu
Dr. Cella Discusses Axitinib and Sorafenib Axis Trial
onclive.com — “Dr. Cella From Northwestern University Feinberg School of Medicine Discusses Axitinib and Sorafenib Axis Trial” View full resource at onclive.com
Most Recently Shared on June 17, 2011 at 5:28 pm By:
OncLive TV: Dr. David Cella From @NUFeinbergMed Discusses Axitinib and Sorafenib Axis Trial http://t.co/iibTp4E
Dr. Rini Describes Axitinib's and Sorafenib's Side Effects
onclive.com — “Dr. Brian I. Rini from the Taussig Cancer Institute Describes Axitinib's and Sorafenib's Side Effects” View full resource at onclive.com
Most Recently Shared on July 6, 2011 at 2:02 pm By:
Brian I. Rini, MD, from the Taussig Cancer Institute @ClevelandClinic Describes Axitinib's and Sorafenib's Side Effects http://t.co/oVf19sZ
Patients treated with sunitinib and sorafenib respond to flu vaccine
eurekalert.org — “Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research.” View full resource at eurekalert.org
Most Recently Shared on June 28, 2011 at 11:29 pm By:
Patients treated with sunitinib and sorafenib respond to flu vaccine: ( American Association for Cancer Research... http://bit.ly/kJHGSb
The Length Of Time Before Breast Cancer Worsens Significantly Improved By Sorafenib
medicalnewstoday.com — “One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the che” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2009 at 5:55 pm By:
MNT Clinical Trials Health News
The Length Of Time Before Breast Cancer Worsens Significantly Improved By Sorafenib: One of the first of a serie.. http://bit.ly/3IO9d1
Therapy For Head And Neck Cancer May Be Improved By Low-Dose Sorafenib
medicalnewstoday.com — “Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life, accord” View full resource at medicalnewstoday.com
Most Recently Shared on May 17, 2011 at 2:55 pm By:
Ear, Nose, and Throat OW Health
Therapy For Head And Neck Cancer May Be Improved By Low-Dose Sorafenib: Adding low doses of the targeted agent s... http://bit.ly/mOgiEH
ingentaconnect Sorafenib/ciclosporin/tacrolimus interaction: Hypertension and ga...
ingentaconnect.com — “ingentaconnect Sorafenib/ciclosporin/tacrolimus interaction: Hypertension and ga...” View full resource at ingentaconnect.com
Most Recently Shared on December 1, 2011 at 9:22 pm By:
Sorafenib/ciclosporin/tacrolimus interaction: Hypertension and gastrointestinal toxicity: 2 case reports: (Sourc... http://t.co/WRNHWVo7
ingentaconnect Sorafenib/sunitinib/temsirolimus: Various toxicities: 19 case rep...
ingentaconnect.com — “ingentaconnect Sorafenib/sunitinib/temsirolimus: Various toxicities: 19 case rep...” View full resource at ingentaconnect.com
Most Recently Shared on April 5, 2011 at 10:26 am By:
Sorafenib/sunitinib/temsirolimus: Various toxicities: 19 case reports: (Source: Reactions) http://bit.ly/eu4eeA
Sorafenib Superior to Sunitinib in Overall Survival in Advanced Hepatocellular Carcinoma - ONA
oncologynurseadvisor.com — “Sunitinib was not found to be effective in improving overall survival in patients with advanced hepatocellular carcinoma compared with sorafenib, according to data reported at the American Society of Clinical Oncology’s 2011 Annual Meeting. However, progression-free survival and time to progression were similar for sunitinib and sorafenib.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 7, 2011 at 4:12 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Sorafenib Superior to Sunitinib in Overall Survival in Advanced Hepatocellular Carcinoma http://goo.gl/fb/WrksT
ingentaconnect Melphalan/sorafenib interaction: Regional squamous cell carcinoma...
ingentaconnect.com — “ingentaconnect Melphalan/sorafenib interaction: Regional squamous cell carcinoma...” View full resource at ingentaconnect.com
Most Recently Shared on April 13, 2011 at 5:09 am By:
Melphalan/sorafenib interaction: Regional squamous cell carcinoma in an elderly patient: case report: (Source: R... http://bit.ly/eE4PR2
Low-Dose Sorafenib May Improve Therapy For Head And Neck Cancer
medicalcenter.osu.edu — “Low-Dose Sorafenib May Improve Therapy For Head And Neck Cancer” View full resource at medicalcenter.osu.edu
Most Recently Shared on May 18, 2011 at 10:14 pm By:
Low-Dose Sorafenib May Improve Therapy For Head And Neck Cancer: COLUMBUS, Ohio – Adding low doses of the target... http://bit.ly/lLOH7l
Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced Pancreatic Cancer - MPR
empr.com — “Data from the BAYPAN study presented at the American College of Clinical Oncology’s 2011 Annual Meeting did not support the addition of sorafenib to gemcitabine therapy in the treatment of advanced pancreatic cancer (APC), in contrast to an earlier Phase I study that demonstrated that this combination was well tolerated and had activity in APC patients.” View full resource at empr.com
Most Recently Shared on June 6, 2011 at 9:01 pm By:
#asco2011 Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced… http://goo.gl/fb/XYOKi
Cancer treatment: Patients treated with sunitinib and sorafenib respond to flu vaccine
sciencedaily.com — “Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a new study.” View full resource at sciencedaily.com
Most Recently Shared on June 28, 2011 at 11:29 pm By:
Cancer treatment: Patients treated with sunitinib and sorafenib respond to flu vaccine: Patients treated with su... http://bit.ly/j6GK2l
Low-dose sorafenib may improve therapy for head and neck cancer
medicalxpress.com — “Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James ...” View full resource at medicalxpress.com
Most Recently Shared on May 16, 2011 at 3:22 pm By:
PhysOrg Health News Health News
Low-dose sorafenib may improve therapy for head and neck cancer http://tw.medicalxpress.com/224763750
Medical News: ENDO: Sorafenib Active in Advanced Thyroid Cancer - in Meeting Coverage, ENDO from MedPage Today
medpagetoday.com — “WASHINGTON -- Two-thirds of patients with advanced thyroid cancer benefited from treatment with the tyrosine kinase inhibitor sorafenib (Nexavar), data from a small clinical trial showed.” View full resource at medpagetoday.com
Most Recently Shared on June 19, 2009 at 3:44 pm By:
CLINICAL TRIALS• ENDO: Sorafenib Active in Advanced Thyroid Cancer (CME/CE) http://tinyurl.com/nr6ltx
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
MNT Colds / Flu News
The latest cold, flu and SARS news published daily. Articles from research centers, universities and prestigious journals.
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
-
Editor
Editors of Oncology & Biotech News/Oncology Net Guide/OncNurse/Contemporary Oncology, on cancer news from pharma, trials, technology, & more.
Advertisement
